The deaths of three study participants led Novartis to halt development of rap-cel in multiple indications, while “transient” side effects led Bristol Myers to voluntarily pause its zola-cel program.
Market Samachar is a news aggregator. This article was originally published by Biopharmadive.com. Tap the button above to read the full story on their site.